🔹 EPS: $0.45 (Est. $0.50) 🔴
🔹 Revenue: $1.114B (Est. $1.103B) 🟢; UP +8% YoY
2025 Guidance:
🔹 Revenue: $4.60B (14% growth)
🔹 Non-GAAP Gross Profit Margin: ~64%-65%
🔹 Non-GAAP Operating Margin: ~21%
🔹 Adjusted EBITDA Margin: ~30%
Q4'24 Segment & Geographical Performance:
🔹 U.S. Revenue: $796.2M (UP +4% YoY) 🟡
🔹 International Revenue: $317.8M (UP +17% YoY) 🟢
Key Metrics:
🔹 Non-GAAP Gross Profit: $661.2M (59.4% margin; Est. 62.34%) 🔴
🔹 Non-GAAP Operating Income: $209.5M (18.8% margin)
🔹 GAAP Net Income: $151.7M; Non-GAAP Net Income: $177.8M
🔹 Cash & Liquidity: $2.58B in cash and equivalents
Strategic and Business Updates:
🔸 Submitted Dexcom G7 15-day CGM system to FDA for review
🔸 Secured reimbursement for Dexcom ONE+ in France, expanding access to CGM for Type 2 diabetes patients
🔸 Announced partnership with ŌURA to integrate glucose data with activity, sleep, and stress metrics
🔸 Launched generative AI-powered features to provide personalized glucose insights
Management Commentary:
🔸 Kevin Sayer, Chairman and CEO:
“In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo, and submitted our G7 15-day product to the FDA. As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.”